Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 3039.

https://doi.org/10.1182/blood.V122.21.3039.3039

Published: 2013

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Jorge E Romaguera, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Luis E Fayad, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Maria Alma Rodriguez, MD, Pam Weaver, Kim Hartig, Maria Badillo, BS, Larry W. Kwak, MD, PhD, Anas Younes, MD, Barbara Pro, MD, Michael Wang, MD

Blood (2013) 122 (21): 5122.

https://doi.org/10.1182/blood.V122.21.5122.5122

Published: 2013

Journal Articles

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Nathan H Fowler, MD, Sattva S. Neelapu, MD, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Robert Z. Orlowski, M.D., Ph.D., Michael Wang, M.D., Francesco Turturro, MD, Yasuhiro Oki, MD, Linda Catherine Lacerte, RN, Felipe Samaniego, MD, MPH

Blood (2012) 120 (21): 901.

https://doi.org/10.1182/blood.V120.21.901.901

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.

Felipe Samaniego, MD, MPH, Jillian F Wise, BS, Rong-Hua Tao, MD, PhD, Haifeng Zhu, PhD, Xue Ao, MS, Zeming Chen, PhD, Wenzhuo Zhuang, PhD, Frank K Braun, PhD, Rohit Mathur, PhD, Jorge Enrique Romaguera, MD, Luis Fayad, MD, Michael Wang, MD, Peter McLaughlin, MD, Timothy J. McDonnell, MD, PhD, Keyur P. Patel, MD, PhD, Sattva S. Neelapu, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2012) 120 (21): 2406.

https://doi.org/10.1182/blood.V120.21.2406.2406

Published: 2012

Journal Articles

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Nathan H. Fowler, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Maria A. Rodriguez, MD, Barbara Pro, MD, F.B. Hagemeister, MD, Anas Younes, MD, Jatin J Shah, MD, Larry W Kwak, MD, PhD, Diana Rodriguez, Peter McLaughlin, MD

Blood (2011) 118 (21): 99.

https://doi.org/10.1182/blood.V118.21.99.99

Published: 2011

Journal Articles

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Nicolas Batty, MD, Elham Ghonimi, MD, Lei Feng, PhD, Anas Younes, MD, Rodriguez Alma, MD, Elizabeth Wager, MD, Fernando Martinez, MD, MPH, Michael Wang, MD, Peter McLaughlin, MD, Nathan Fowler, MD, Fredrick Hagemeister, MD

Blood (2010) 116 (21): 3357.

https://doi.org/10.1182/blood.V116.21.3357.3357

Published: 2010

Journal Articles

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Paul A. Hamlin, Jr, MD, Maria Alma Rodriguez, MD, Ariela Noy, MD, Carol S. Portlock, MD, David Straus, MD, Peter McLaughlin, MD, Barbara Pro, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Brett Wegner, Otilia Dumitrescu, MD, Neetha Pandit Tasker, MD, Craig H Moskowitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2010) 116 (21): 1793.

https://doi.org/10.1182/blood.V116.21.1793.1793

Published: 2010

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.

Anas Younes, MD, Michelle A. Fanale, MD, Peter McLaughlin, MD, Amanda Copeland, Joy Zhu, Silvania de Castro Faria

Blood (2010) 116 (21): 2830.

https://doi.org/10.1182/blood.V116.21.2830.2830

Published: 2010

Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD

Blood (2009) 114 (22): 3922.

https://doi.org/10.1182/blood.V114.22.3922.3922

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Peter McLaughlin, MD, Sattva Neelapu, MD, Michelle Fanale, MD, Maria Rodriguez, MD, Ana Ayala, RN, Barbara Pro, M.D., F.B. Hagemeister, Anas Younes, Susan Neel, Nathan Fowler, Mark Hess, Larry W. Kwak

Blood (2008) 112 (11): 3056.

https://doi.org/10.1182/blood.V112.11.3056.3056

Published: 2008

Journal Articles

Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom’s Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

Ronjay Rakkhit, MD, Kay B Delasalle, B.S., Maria B. Gavino, R.N., Sheeba K. Thomas, Meletios A Dimopoulos, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Peter McLaughlin, MD, Raymond Alexanian, MD, Donna M. Weber, MD

Blood (2008) 112 (11): 3065.

https://doi.org/10.1182/blood.V112.11.3065.3065

Published: 2008

Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD

Blood (2008) 112 (11): 3051.

https://doi.org/10.1182/blood.V112.11.3051.3051

Published: 2008

Journal Articles

Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients

Ali Mazloom, MD, Valerie K Reed, MD, Fernando Cabanillas, MD, Luis Fayad, MD, Barbara Pro, M.D., Puneeth Iyengar, MD, PhD, Peter McLaughlin, MD, Diana L Urbauer, MS, Bouthaina S. Dabaja, MD

Blood (2008) 112 (11): 3764.

https://doi.org/10.1182/blood.V112.11.3764.3764

Published: 2008

Journal Articles

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

Anas Younes, MD, Amanda Wedgwood, LPN, Peter McLaughlin, MD, Charalambos Andreadis, MD, Sarit E. Assouline, MD, Zuomei Li, Ph.D, Robert E. Martell, MD, Marja Dubay, BSc., Tracy-Ann Patterson, BSc.N, Michelle R. Ward, MD, Michael Crump, MD

Blood (2007) 110 (11): 2571.

https://doi.org/10.1182/blood.V110.11.2571.2571

Published: 2007

Journal Articles

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Anas Younes, MD, Barbara Pro, MD, Michelle Fanale, MD, Peter McLaughlin, MD, Sattva Neelapu, MD, Luis Fayad, MD, Amanda Wedgwood, RN, APN, Daniela Buglio, MD, Tracy Patterson, RN, Marja Dubay, BSc., Zuomei Li, Ph.D., Robert E. Martell, MD, Ph.D., M. Renee Ward, MD, Ph.D., R. Gregory Bociek, MD, MSc., FRCPC

Blood (2007) 110 (11): 2566.

https://doi.org/10.1182/blood.V110.11.2566.2566

Published: 2007

NARROW

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.

Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes.

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom’s Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only